Should I buy STAAR Surgical Company (STAA) stock or is it too late?

STAAR Surgical Company · Health Care · price $22

See the full STAAR Surgical Company (STAA) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Jefferies — 61% of its targets hit on this sector (137 calls tested). It aims for $23 (+7.0 %), call made on September 23, 2026, maturing on September 23, 2027 (21 d ago).

The 2 reliable analysts $21-2.3 %

The 6 other firms $31.50+47 %

How to read it: the 2 reliable firms are not filtered by optimism — 1 aim above the price, 1 below, hence their $21 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on STAAR Surgical Company

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Canaccord Genuity	44 %	+33.4 %	16	$32 +49%
Stephens & Co.	29 %	+18.0 %	7	$17 -21%
BTIG	20 %	-15.5 %	5	$53 +147%
Mizuho	0 %	-42.9 %	6	$27 +26%
Needham	0 %	-31.0 %	9	—

In short — Should you invest in STAAR Surgical Company? Is it too late, still worth it? Analysts are split (50% buy, median target $29, i.e. +35%), and the most reliable on STAA targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $29, i.e. +35% from the current price ($22).
The most reliable firm on STAA, Jefferies (50% hit rate, 2 scored calls), targets $23 (call made on September 22, 2026, maturing on September 22, 2027) (+7%) in its most recent call, and $22 (call made on January 28, 2026, maturing on January 28, 2027) (+0%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 3 are neutral and 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on STAA

Median target $29 (+35%) · 8 ratings · Hold consensus

Strong Buy00%

Buy450%

Hold338%

Sell113%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in STAAR Surgical Company now?

We won't decide for you. The facts: 50% of analysts rate it a buy, median target $29 (+35%), and Jefferies (most reliable on STAA, 50%) targets $23. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in STAAR Surgical Company?

Not according to analysts: the median target ($29) is still +35% above the current price ($22) (most reliable on STAA: Jefferies, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is STAAR Surgical Company still worth investing in?

It depends on the gap between the price ($22) and its estimated value: analysts target $29 on median (+35%), with 50% buys (most reliable on STAA: Jefferies, 50%). Cross-check with their real reliability on STAA and the cautions above. Information, not advice.

What's the main risk in buying STAA?

The consensus is not unanimous: of 8 ratings, 3 are neutral and 1 is a sell.

→ Go deeper: the full STAAR Surgical Company profile (consensus, analyst reliability, price target, performance).